All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
MPN Hub spotlight: Ruxolitinib for MF
Do you know... What was the median duration of SVR35 response in patients with myelofibrosis treated with ruxolitinib in the COMFORT-I and COMFORT-II trials?
Ruxolitinib, an oral Janus kinase 1/2 (JAK1/JAK2) inhibitor, was first approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of patients with intermediate- or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera (PV) MF, and post-essential thrombocythemia MF, and remains a mainstay of treatment for these patients.1,2 Ruxolitinib targets primary drivers of MF including constitutive Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway activation, thereby regulating inflammatory cytokine signaling and hematopoiesis.1,3
The phase III COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544) trials demonstrated spleen and symptom responses of ruxolitinib 15–20 mg twice daily at Week 24 and Week 48, respectively, in patients with intermediate-2 or high-risk MF.4,5
Ruxolitinib is now under investigation in new formulations and in combination with other agents in several ongoing trials. Explore our mini-module to find out more.
This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
